From another site: "The facts provide inconvenient truths for bashers. IB is a global company after 2 years (really only 1 full year after the J-Code award)
The Saudi launch is imminent. The EU launch is near. The Covid study is moving forward. The FDA decision on sBLA acceptance is near. BC-P is 3x BC-CIS. The Saudi are likely to approve the entire Bioshield platform in 2026. China will be enormous and more of Asia is likely to be added, The NCCN update. Treatment for Lymphopenia like epogen and neupogen due to low ALC detection. rBCG to eliminate shortages during treatment (I have personal experience with this one)
Revenue is going up by a lot in 2026. NANT Leonard (CAR-NX) hasn't even been factored into the valuation. Sepsis is huge. BCG Naive is going to readout this year and become a standard of care. Cancer driven by Lynch Syndrome will be eliminated. And more and more events. The valuation will grow as global recognition overwhelms doubters. GBM patients have hope. IB is already the most exciting pharma on the planet.
Valuation is going to exceed all expectations. I can't tell you when and no one else can. Only the market will decide but up over coming months is inevitable. Nothing else matters......"sirocco
Market Data 
Markets 
AI
